Meeting
2023 ASCO Annual Meeting
A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non–small-cell lung cancer.
Authors
Sarah B. Goldberg
Yale Cancer Center, Yale School of Medicine, New Haven, CT
Sarah B. Goldberg , Salman Rafi Punekar , Vamsidhar Velcheti , Jonathan W. Riess , Katherine Ann Scilla , Jennifer W Carlisle , Katerina A. Politi , Jong Woo Lee , Thomas J. Myers , Linda J. Paradiso , Barbara Burtness
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05374538
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9140)
DOI
10.1200/JCO.2023.41.16_suppl.TPS9140
Abstract #
TPS9140
Poster Bd #
127b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).
First Author: David S. Hong
Poster
2023 ASCO Annual Meeting
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.
First Author: Jordan Kardos
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk
Poster
2020 ASCO Virtual Scientific Program
A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.
First Author: Stephen V. Liu